Table 1.
General characteristics of the patients.
| Parameter | Sample | Aspirin | Clopidogrel | Ticagrelor | p Value |
|---|---|---|---|---|---|
| n (%) | 193 (100) | 191 (98.96) | 41 (21.24) | 148 (76.68) | NA |
| Age mean ± SD | 58.54 ± 13.34 | 58.40 ± 13.34 | 65.29 ± 13.84 | 56.74 ± 12.81 | 0.001 |
| Age < 50 years n (%) | 57 (29.53) | 57 (29.84) | 5 (12.19) | 52 (35.13) | 0.005 |
| Men n (%) | 138 (71.50) | 137 (71.72) | 28 (68.39) | 109 (73.64) | 0.497 |
| Weight mean ± SD | 84.14 ± 16.19 | 84.19 ± 16.22 | 83.02 ± 17.20 | 84.79 ± 15.91 | 0.541 |
| Weight > 70 kg n (%) | 158 (84.04) | 157 (83.95) | 31 (77.50) | 126 (86.89) | 0.142 |
| Diagnosis | |||||
| Myocardial infarction n (%) | 166 (86.01) | 164 (85.86) | 26 (63.41) | 140 (94.59) | <0.001 |
| STEMI n (%) | 127 (65.80) | 126 (65.96) | 18 (43.90) | 109 (73.64) | <0.001 |
| Laboratory parameters | |||||
| Renal dysfunction n (%) | 41 (21.57) | 41 (21.80) | 13 (32.50) | 27 (18.49) | 0.056 |
| Platelets > 291,000 n (%) | 43 (22.75) | 43 (22.99) | 8 (20.00) | 34 (23.44) | 0.645 |
| PDW median (IQR) | 12.00 (11.00–13.35) | 12.00 (11.00–13.40) | 12.20 (11.05–13.37) | 11.90 (10.90–13.45) | 0.350 |
| MPV median (IQR) | 10.40 (9.90–11.00) | 10.40 (9.90–11.00) | 10.40 (10.02–11.17) | 10.40 (9.80–11.00) | 0.341 |
| MPV > 10/fL | 128 (67.72) | 127 (67.91) | 30 (75.00) | 95 (65.51) | 0.257 |
| P-LCR median (IQR) | 28.40 (23.85–33.40) | 28.40 (24.00–33.40) | 29.15 (24.97–33.80) | 28.30 (23.30–33.40) | 0.342 |
| PCT median (IQR) | 0.26 (0.22–0.29) | 0.26 (0.22–0.29) | 0.24 (0.21–0.29) | 0.26 (0.22–0.29) | 0.231 |
| PCT > 0.26/fL | 86 (45.50) | 85 (45.45) | 13 (32.50) | 70 (48.27) | 0.076 |
| Leukocytosis n (%) | 102 (53.96) | 101 (54.01) | 16 (40.00) | 86 (59.31) | 0.030 |
| Anaemia n (%) | 43 (22.75) | 43 (22.99) | 13 (32.50) | 29 (20.00) | 0.095 |
| Risk factors | |||||
| Smoking n (%) | 70 (37.83) | 69 (37.50) | 5 (13.15) | 64 (45.07) | <0.001 |
| Diabetes n (%) | 42 (21.76) | 42 (21.98) | 8 (19.51) | 31 (20.94) | 0.841 |
| Hypertension n (%) | 123 (63.73) | 121 (63.35) | 30 (73.17) | 89 (60.13) | 0.126 |
| Dyslipidemia n (%) | 131 (70.81) | 129 (70.49) | 25 (64.10) | 102 (71.83) | 0.350 |
| Hypercholesterolaemia n (%) | 50 (27.17) | 49 (26.92) | 9 (23.07) | 40 (28.36) | 0.511 |
| Hypertriglyceridaemia n (%) | 94 (51.08) | 92 (50.54) | 15 (38.46) | 76 (53.90) | 0.088 |
| HipoHDL n (%) | 69 (37.29) | 67 (36.61) | 14 (35.89) | 53 (37.32) | 0.870 |
| LDL > 70 mg/dL n (%) | 135 (73.77) | 134 (74.03) | 25 (64.10) | 107 (76.42) | 0.122 |
| Family history of CVDs n (%) | 41 (23.69) | 41 (23.97) | 5 (13.51) | 36 (27.06) | 0.088 |
| Overweight/obesity n (%) | 139 (78.08) | 138 (77.97) | 29 (78.37) | 109 (78.98) | 0.936 |
| ADP test median (IQR) | NA | NA | 25.00 (18.00–33.00) | 19.00 (14.25–24.00) | <0.001 |
| LTPR n (%) | NA | NA | 12 (29.27) | 70 (47.30) | 0.039 |
| MTPR n (%) | NA | NA | 27 (65.85) | 76 (51.35) | 0.098 |
| HTPR n (%) | NA | NA | 2 (4.88) | 2 (1.35) | NA |
| ASPI test median (IQR) | NA | 17.00 (11.00–26.00) | 24.00 (11.00–38.00) | 15.50 (11.00–24.00) | 0.023 |
| HTPR n (%) | NA | 83 (43.46) | 25 (60.97) | 57 (39.04) | 0.012 |
| T2 n (%) | 85 (44.04) | 85 (44.50) | 14 (34.14) | 70 (47.30) | 0.134 |
The p-value refers to the comparison between patients treated with clopidogrel and ticagrelor. SD—standard deviation; PDW—platelet volume distribution width; MPV—mean platelet volume; P-LCR—platelet larger cell ratio; PCT—plateletcrit, STEMI—ST-Elevation Myocardial Infarction; CVDs—cardiovascular disease; NA—not applicable. Renal dysfunction: serum creatinine level higher than 1.2 mg/dL for men and higher than 0.9 mg/dL for women. IQR—interquartile range; T2—lockdown during the COVID-19 pandemic.